Mylan launches women's care products in India

The portfolio focuses on therapies such as hormones, pre- and post-natal nutrition and management of premenstrual syndrome

Global pharmaceutical major Mylan Inc stated its subsidiary, Mylan Pharmaceuticals Private Limited, had launched a portfolio of ‘Women’s Care’ products in India.

The portfolio, which initially will consist of eight products, focuses on therapies such as hormones, pre- and post-natal nutrition and management of premenstrual syndrome (PMS). This launch builds on Mylan's launch of a comprehensive portfolio of antiretroviral products in India last year.

“The launch of Mylan’s Women's Care portfolio expands and strengthens our growing commercial platform in India and further delivers on our commitment to provide the world's population with access to high quality medicine,” Mylan chief executive officer, Heather Bresch, stated in a press release here on Friday

According to Bresch, women’s care represents a high-growth therapeutic category in India and an opportunity for Mylan to help satisfy unmet medical needs.

Approximately one in five pregnancies in Indian women ends in miscarriage, and it is estimated that the number of infertile couples in India is around 12 million.

“A key challenge in Women’s Health continues to be how to address the risks of miscarriages, infertility and nutritional deficiencies. In addition to launching our innovative, high quality product portfolio, Mylan will help to strengthen the capabilities of healthcare providers in this area through training programmes and workshops, working together with the medical community to address areas of concern in women’s health and improve timely access to appropriate high quality treatment,” he said.

 
Mylan president, Rajiv Malik ,said that with the addition of the Women's Care portfolio, Mylan's commercial platform would be increasingly well-positioned to serve the fast growing Indian market.